Literature DB >> 32024773

A Novel Immunogen Selectively Eliciting CD8+ T Cells but Not CD4+ T Cells Targeting Immunodeficiency Virus Antigens.

Hiroshi Ishii1, Kazutaka Terahara2, Takushi Nomura1, Akiko Takeda1, Midori Okazaki1, Hiroyuki Yamamoto1, Tsuyoshi Tokusumi3, Tsugumine Shu3, Tetsuro Matano4,5.   

Abstract

Optimization of immunogen is crucial for induction of effective T-cell responses in the development of a human immunodeficiency virus (HIV) vaccine. Conventional T-cell-based vaccines have been designed to induce virus-specific CD4+ T as well as CD8+ T cells. However, it has been indicated that induction of HIV-specific CD4+ T cells, preferential targets for HIV infection, by vaccination may be detrimental and accelerate viral replication after HIV exposure. In the present study, we present a novel immunogen to selectively induce CD8+ T cells but not CD4+ T cells targeting viral antigens. The immunogen, CaV11, was constructed by tandem connection of overlapping 11-mer peptides spanning simian immunodeficiency virus (SIV) Gag capsid (CA) and Vif. Prime-boost immunization with DNA and Sendai virus (SeV) vectors expressing CaV11 efficiently induced Gag/Vif-specific CD8+ T-cell responses with inefficient Gag/Vif-specific CD4+ T-cell induction in rhesus macaques (n = 6). None of the macaques exhibited the enhancement of acute viral replication after an intravenous high-dose SIV challenge, which was observed in those immunized with DNA and SeV expressing the whole Gag protein in our previous study. Set point viral control postinfection was associated with SeV-specific CD4+ T-cell responses postimmunization, suggesting contribution of SeV-specific helper responses to effective Gag/Vif-specific CD8+ T-cell induction by vaccination. This immunogen design could be a promising method for selective induction of effective anti-HIV CD8+ T-cell responses.IMPORTANCE Induction of effective CD8+ T-cell responses is an important HIV vaccine strategy. Several promising vaccine delivery tools have been developed, and immunogen optimization is now crucial for effective T-cell induction. Conventional immunogens have been designed to induce virus-specific CD4+ T cells as well as CD8+ T cells, but induction of virus-specific CD4+ T cells that are preferential targets for HIV infection could enhance acute HIV proliferation. Here, we designed a novel immunogen to induce HIV-specific CD8+ T cells without HIV-specific CD4+ T-cell induction but with non-HIV antigen-specific CD4+ T-cell help. Our analysis in a macaque AIDS model showed that our immunogen can efficiently elicit effective CD8+ T but not CD4+ T cells targeting viral antigens, resulting in no enhancement of acute viral replication after virus exposure. This immunogen design, also applicable for other currently developed immunogens, could be a promising method for selective induction of effective anti-HIV CD8+ T-cell responses.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  CD4; HIV; SIV; T cell; vaccine

Mesh:

Substances:

Year:  2020        PMID: 32024773      PMCID: PMC7108830          DOI: 10.1128/JVI.01876-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239.

Authors:  Nancy A Wilson; Jason Reed; Gnankang S Napoe; Shari Piaskowski; Andy Szymanski; Jessica Furlott; Edna J Gonzalez; Levi J Yant; Nicholas J Maness; Gemma E May; Taeko Soma; Matthew R Reynolds; Eva Rakasz; Richard Rudersdorf; Adrian B McDermott; David H O'Connor; Thomas C Friedrich; David B Allison; Amit Patki; Louis J Picker; Dennis R Burton; Jing Lin; Lingyi Huang; Deepa Patel; Gwendolyn Heindecker; Jiang Fan; Michael Citron; Melanie Horton; Fubao Wang; Xiaoping Liang; John W Shiver; Danilo R Casimiro; David I Watkins
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Ending AIDS--is an HIV vaccine necessary?

Authors:  Anthony S Fauci; Hilary D Marston
Journal:  N Engl J Med       Date:  2014-02-06       Impact factor: 91.245

3.  Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen.

Authors:  T Matano; M Kano; H Nakamura; A Takeda; Y Nagai
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  HIV preferentially infects HIV-specific CD4+ T cells.

Authors:  Daniel C Douek; Jason M Brenchley; Michael R Betts; David R Ambrozak; Brenna J Hill; Yukari Okamoto; Joseph P Casazza; Janaki Kuruppu; Kevin Kunstman; Steven Wolinsky; Zvi Grossman; Mark Dybul; Annette Oxenius; David A Price; Mark Connors; Richard A Koup
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

5.  A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression.

Authors:  H O Li; Y F Zhu; M Asakawa; H Kuma; T Hirata; Y Ueda; Y S Lee; M Fukumura; A Iida; A Kato; Y Nagai; M Hasegawa
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  Strong TH1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy.

Authors:  Venkateswarlu Chamcha; Pradeep B J Reddy; Sunil Kannanganat; Courtney Wilkins; Sailaja Gangadhara; Vijayakumar Velu; Richard Green; G Lynn Law; Jean Chang; James R Bowen; Pamela A Kozlowski; Michelle Lifton; Sampa Santra; Traci Legere; Lynette S Chea; Lakshmi Chennareddi; Tianwei Yu; Mehul S Suthar; Guido Silvestri; Cynthia A Derdeyn; Michael Gale; Francois Villinger; Eric Hunter; Rama Rao Amara
Journal:  Sci Transl Med       Date:  2019-11-20       Impact factor: 17.956

7.  Biphasic CD8+ T-Cell Defense in Simian Immunodeficiency Virus Control by Acute-Phase Passive Neutralizing Antibody Immunization.

Authors:  Sumire Iseda; Naofumi Takahashi; Hugo Poplimont; Takushi Nomura; Sayuri Seki; Taku Nakane; Midori Nakamura; Shoi Shi; Hiroshi Ishii; Shota Furukawa; Shigeyoshi Harada; Taeko K Naruse; Akinori Kimura; Tetsuro Matano; Hiroyuki Yamamoto
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

Review 8.  Impact of MHC class I diversity on immune control of immunodeficiency virus replication.

Authors:  Philip J R Goulder; David I Watkins
Journal:  Nat Rev Immunol       Date:  2008-08       Impact factor: 53.106

9.  Impact of cytotoxic-T-lymphocyte memory induction without virus-specific CD4+ T-Cell help on control of a simian immunodeficiency virus challenge in rhesus macaques.

Authors:  Tetsuo Tsukamoto; Akiko Takeda; Takuya Yamamoto; Hiroyuki Yamamoto; Miki Kawada; Tetsuro Matano
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

10.  Defective CD8 T cell memory following acute infection without CD4 T cell help.

Authors:  Joseph C Sun; Michael J Bevan
Journal:  Science       Date:  2003-04-11       Impact factor: 47.728

View more
  2 in total

1.  Env-independent protection of intrarectal SIV challenge by vaccine induction of Gag/Vif-specific CD8+ T cells but not CD4+ T cells.

Authors:  Hiroshi Ishii; Kazutaka Terahara; Takushi Nomura; Midori Okazaki; Hiroyuki Yamamoto; Tsugumine Shu; Hiromi Sakawaki; Tomoyuki Miura; David I Watkins; Tetsuro Matano
Journal:  Mol Ther       Date:  2022-02-26       Impact factor: 12.910

2.  Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses.

Authors:  Hiroshi Ishii; Takushi Nomura; Hiroyuki Yamamoto; Masako Nishizawa; Trang Thi Thu Hau; Shigeyoshi Harada; Sayuri Seki; Midori Nakamura-Hoshi; Midori Okazaki; Sachie Daigen; Ai Kawana-Tachikawa; Noriyo Nagata; Naoko Iwata-Yoshikawa; Nozomi Shiwa; Tadaki Suzuki; Eun-Sil Park; Maeda Ken; Taishi Onodera; Yoshimasa Takahashi; Kohji Kusano; Ryutaro Shimazaki; Yuriko Suzaki; Yasushi Ami; Tetsuro Matano
Journal:  Cell Rep Med       Date:  2022-01-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.